RPL34 as A Potential Drug Target Or Biomarker for Leukemia (G6164)

Target Name: RPL34

NCBI ID: G6164

RPL34

RPL34 as A Potential Drug Target Or Biomarker for Leukemia

RPL34 (regeneration-associated protein 34) is a protein that is expressed in various tissues of the human body, including the bone marrow, where it is involved in the regulation of cell proliferation and differentiation. RPL34 has also been shown to play a role in the development and progression of various diseases, including leukemia. As a result, RPL34 has potential as a drug target or biomarker for the treatment of leukemia and other diseases.

The Role of RPL34 in Leukemia

Leukemia is a type of cancer that affects the bone marrow and blood cells. In leukemia, the cells of the bone marrow produce abnormal white blood cells, which do not function properly and can accumulate in the bone marrow and bloodstream. This can lead to a variety of symptoms, including anemia, fever, and an increased risk of infections.

RPL34 has been shown to be involved in the regulation of leukemia cell proliferation and differentiation. Studies have shown that RPL34 can inhibit the activity of the oncogene transforming growth factor 尾 (TGF-β), which promotes the growth and proliferation of leukemia cells. In addition, RPL34 has been shown to play a role in the regulation of the apoptosis (programmed cell death) pathway, which is a mechanism by which leukemia cells are programmed to die and are removed from the bone marrow.

The potential implications of targeting RPL34 with drugs or other therapeutic agents are significant. By inhibiting the activity of RPL34, researchers may be able to reduce the growth and proliferation of leukemia cells, leading to a reduction in the number of leukemia cells in the bone marrow and a decrease in the severity of symptoms.

The Potential as a Biomarker

In addition to its role in leukemia, RPL34 has also been shown to be involved in the regulation of normal cell function and development. This makes it a potential biomarker for the diagnosis and prognosis of various diseases.

For example, studies have shown that RPL34 is involved in the regulation of cell adhesion, which is the process by which cells stick together and form tissues. This regulation is important for the development and maintenance of tissues and organs, including blood vessels and brain tissue.

In addition, RPL34 has been shown to be involved in the regulation of the cytoskeleton, which is the structure that gives cells shape and stability. This regulation is important for the movement and function of cells, including the formation of blood cells.

The potential use of RPL34 as a biomarker for diseases is significant. By identifying individuals with elevated levels of RPL34, researchers may be able to diagnose and monitor various diseases, including leukemia. In addition, by targeting RPL34 with drugs or other therapeutic agents, researchers may be able to reduce the severity and progression of these diseases.

Conclusion

RPL34 is a protein that is involved in the regulation of various cellular processes that are important for the development and maintenance of tissues and organs. In addition, RPL34 has been shown to play a role in the regulation of leukemia cell proliferation and differentiation. As a result, RPL34 has potential as a drug target or biomarker for the treatment of leukemia and other diseases. Further research is needed to fully understand the role of RPL34 in these processes and to develop effective treatments for these diseases.

Protein Name: Ribosomal Protein L34

Functions: Component of the large ribosomal subunit (PubMed:12962325, PubMed:23636399, PubMed:25957688, PubMed:25901680, PubMed:32669547). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:12962325, PubMed:23636399, PubMed:25957688, PubMed:25901680, PubMed:32669547)

The "RPL34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets